



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 08/13/2026

Medications for Multiple Sclerosis

Briumvi™ (ublituximab-xiiv)

Lemtrada® (alemtuzumab)

Ocrevus® (ocrelizumab)

Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq)

HCPCS: Brriumvi: J2329; Lemtrada : J0202; Ocrevus: J2350; Ocrevus Zunovo: J2351

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. FDA approved age
 - b. FDA approved indication
 - c. Will not be used in combination with other disease-modifying treatments of multiple sclerosis (MS)
 - d. Trial and failure, contraindication, OR intolerance to the preferred drugs as listed in BCBSM/BCN's utilization management medical drug list
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limitations: Align with FDA recommended dosing and duration of treatment.
 - b. Authorization Period: One year at a time.
 - c. Renewal Criteria: Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit, such as disease stability or improvement

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Multiple sclerosis (MS) is a chronic progressive inflammatory autoimmune disease of the central nervous system, involving axonal deterioration and demyelination. Signs and symptoms vary greatly and can include blurry or double vision, muscle weakness and stiffness, tingling in limbs, fatigue, difficulty concentrating, and many other debilitating symptoms. MS typically presents between the ages of 20 and 45, and women are affected by MS three times more frequently than men. Onset of symptoms before age 21 occurs in 3-5% of cases and is considered juvenile MS.
- Several clinical presentations of MS have been identified including relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and a rare form called progressive-relapsing (PRMS). All forms of MS are associated with neurologic dysfunction. Relapsing-remitting MS affects the majority of newly diagnosed individuals and about half of the people diagnosed with RRMS will transition to SPMS within 10-20 years of initial diagnosis. Relapses are characterized as periods of sudden worsening of symptoms or new symptoms. Often, the periods of remission between relapses will last weeks, months, or even years.
- Patients diagnosed with PPMS experience continued and gradual physical decline without remissions. PPMS affects as many men as women and typically presents after the age of 40. PRMS affects only about 5% of patients diagnosed with MS and is characterized by steady worsening dysfunction with distinct exacerbations.
- The American Academy of Neurology (AAN) 2018 treatment guidelines for adults with MS state that there are a variety of disease modifying therapies (DMTs) available; therefore, evaluating patient preference may improve acceptance and adherence to DMT. Considerations when choosing DMT include safety, route of administration, lifestyle, cost, efficacy, common adverse effects, tolerability, comorbid conditions, and concomitant medications. Recommendations for first-line therapy are not specified, with the exception of Lemtrada (alemtuzumab), Tysabri (natalizumab), and Gilenya® (fingolimod) for highly active MS and Ocrevus (ocrelizumab) for primary progressive MS.
- There are no formal guidelines for the treatment of pediatric MS which is rare. Less than 5,000 children and teens are living with MS in the United States. Pediatric patients with MS typically experience more frequent relapses compared to adults with MS but recover from relapses more quickly than adults. Although Gilenya and Tascenso ODT are the only approved therapies for pediatric MS, many of the disease modifying therapies prescribed for adults with MS are also prescribed for pediatric MS based on supporting data such as small retrospective studies and case studies.

References:

1. Drug Facts and Comparisons. eFacts (online). 2022. Available from Wolters Kluwer Health, Inc. Accessed January 3, 2023.
2. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology*. 2018;90:777-788. Available at: <https://n.neurology.org/content/neurology/90/17/777.full.pdf>. Accessed on May 25, 2026.
3. Lotze TE. Treatment and prognosis of pediatric multiple sclerosis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on January 3, 2023).
4. National Multiple Sclerosis Society. Pediatric MS. Available at: <https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Pediatric-MS>. Accessed on January 3, 2023.
5. IPD Analytics. Payer & Provider Insights. January 2022. Accessed January 3, 2023. <https://www.ipdanalytics.com>
6. Tyruko [prescribing information]. Princeton, NJ: Sandoz, Inc.; August 2023
7. Ocrevus Zunovo [prescribing information]. South San Francisco, CA: Genetech, Inc; September 2024.

Policy History		
#	Date	Change Description
3.3	Effective Date: 08/13/2026	Added requirement for Tascenso ODT that member must be unable to swallow tablets or capsules.
3.2	Effective Date: 06/22/2026	UM medical management system update for MAPPO and BCNA for Briumvi, Ocrevus, and Ocrevus Zunovo
3.1	Effective Date: 10/09/2025	Annual review.
3.0	Effective Date: 10/03/2024	Updated policy to include Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) Removed: Aubagio, Bafiertam, Betaseron, Tecfidera, Gilenya, Copaxone, Kesimpta, Mayzent, Plegridy, and Ponvory from list of products which will now refer to the General Utilization Management Policy for criteria. UM medical management system update for BCBSM and BCN for Ocrevus Zunovo
2.9	Effective Date: 10/12/2023	Updated policy to include Tyruko Added criteria for biosimilar products
2.8	Effective Date: 02/02/2023	Updated policy to include Briumvi
2.7	Effective Date: 01/26/2023	UM medical management system update for BCBSM and BCN for Briumvi
2.6	Effective Date: 10/06/2022	Added Mavenclad and generic Copaxone back to policy
2.5	Effective Date: 02/10/2022	Added Tascenso to the policy
2.4	Effective Date: 06/10/2021	Added Ponvory to the policy
2.3	Effective Date: 10/08/2020	Added Kesimpta to the policy
2.2	Effective Date: 06/11/2020	Updated policy to new template and to include Bafiertam and Zeposia. Criteria has been updated to reflect what is currently implemented.
2.1	Effective Date: 12/05/2019	Added Vumerity to the policy
2.0	Effective Date: 10/01/2019	UM medical management system update for BCBSM and BCN for Ocrevus and Lemtrada
1.9	Effective Date: 08/15/2019	Updated criteria for Ocrevus, Lemtrada, and Tysabri to be just indication only After MBDC: Removed investigational use sections from drug specific criteria due to updated indications for many MS medications
1.8	Effective Date: 06/06/2019	Added criteria for Mayzent and Mavenclad Deleted Zinbryta (withdrawn by the FDA due to safety issues), Updated criteria to FDA approved age/indication Updated criteria to reflect t/f of BCBSM/BCN preferred drugs Updated QL to FDA approved dosing
1.7	Effective Date: 02/14/2019	Quantity Limit Update for Lemtrada
1.6	Effective Date: 08/09/2018	Annual Review of Medical Policy
1.5	Effective Date: 07/01/2018	UM medical management system update to be removed for Ocrevus and Lemtrada
1.4	Effective Date: 08/10/2017	Added criteria for Ocrevus Changes to step therapies for Lemtrada and Tysabri

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

1.3	Effective Date: 05/04/2017	New Drug for Ocrevus
1.2	Effective Date: 11/10/2016	Added criteria for Zinbryta and preliminary criteria for Ocrevus
1.1	Effective Date: 08/11/2016	Criteria Update: MD attestation and Lemtrada QL and Authorization Criteria
1.0	Effective Date: 08/13/2015	MS Disease Modifying Agents Coverage Guidelines (Class Review)

** The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.*

Blue Cross Blue Shield/Blue Care Network of Michigan

Medication Authorization Request Form



This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. ☐ Male ☐ Female	Address
Diagnosis	City /State/Zip
Drug Name	Phone/Fax: P: () - F: () -
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.

STEP 1: DISEASE STATE INFORMATION

- Is this request for: ☐ Initiation ☐ Continuation *Date patient started therapy:* _____
- Administered by patient or a medical professional? ☐ patient (self) ☐ health care professional (physician, nurse, etc.)
- Site of administration? ☐ Provider office/Home infusion ☐ Other: _____
☐ Hospital outpatient facility (go to #4) *Reason for Hospital Outpatient administration:* _____
☐ Hospital inpatient facility for Car-T therapy only (for example: Kymriah, Yescarta, or Tecartus) (go to #5)
- Please specify location of administration if hospital outpatient infusion: _____
- Please specify location of administration if hospital inpatient infusion: _____
- Please provide the NPI number for the place of administration: _____
- Initiation AND Continuation of therapy:**
 - What is the patient's diagnosis? _____
 - What other medication has the patient received for their condition? Please list _____
 - Please describe the response to previous therapies: _____
 - Will the patient be receiving any other treatment for the listed condition while on this medication? Please list: _____
 - Please list any labs values important for diagnosing or monitoring this patient's condition: _____
- Continuation of therapy:**
 - Has the patient progressed while on this medication? ☐ yes ☐ no
 - How has the patient's condition changed while on this medication?

☐ Improved: Please describe: _____
 ☐ Stable: please describe: _____
 ☐ Worsened; Please describe: _____
 ☐ Other; Please describe: _____

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

7/26/2018, 9/18/2018; 1/31/2020; 3/17/2020; 8/9/2021